Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs

Issues involving inspectional readiness and the drug master production record cited in agency's refusal to review Acorda's Inbrija in Parkinson's disease; SteadyMed faces request for additional design verification and validation testing for drug/device combo Trevyent in pulmonary arterial hypertension.

The US FDA turned away two new drug applications (NDAs) submitted under 505(b)(2) in the last week of August – actions that, once again, highlight the fallacy of viewing this regulatory pathway as an easier route to approval relative to a regular 505(b)(1) NDA.

On Aug. 29, Acorda Therapeutics Inc. announced receipt of a refuse-to-file (RTF) letter for Inbrija (levodopa inhalation powder, formerly...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America